Perjeta 420 MG/14 ML vial 14ML
Ended Awarded
- Contract number
- SPE2DB25FDJ18
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $36,458
Award facts
- Contract value 100% obligated
- $36,458.16 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $36,458.16 by the Defense Logistics Agency (DLA) on April 29, 2025. The delivery order, which has an ultimate completion date of May 20, 2025, is for the supply of Perjeta 420 mg/14 ml vials. This award was issued without a set-aside designation, allowing the vendor to compete on an unrestricted basis in the federal procurement marketplace. The delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the SPE2DB program, a $499,999,999 single-award vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products for military health facilities.
The DLA, which operates under the Department of Defense, uses its pharmaceutical supply contracts to support medical supply needs across military healthcare systems worldwide. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, with a robust portfolio of delivery orders covering prescription medications, biologics, and specialty pharmaceuticals. The company's consistent success in securing contracts with the DLA reflects its capability to reliably distribute branded and generic drugs, oncology treatments, and other specialized pharmaceutical products to Department of Defense healthcare facilities nationwide.
Quick answers
Who was awarded contract SPE2DB25FDJ18?
SPE2DB25FDJ18 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on April 29, 2025.
How much is contract SPE2DB25FDJ18 worth?
The government has obligated $36,458 on SPE2DB25FDJ18.
Is contract SPE2DB25FDJ18 an order under another contract?
Yes. SPE2DB25FDJ18 is a delivery order under SPE2DB22D9239, an indefinite delivery contract.
Was contract SPE2DB25FDJ18 competed?
The extent of competition for SPE2DB25FDJ18 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award